Trial Profile
A proof of principle trial of alpha-1 antitrypsin in patients with graft versus host disease.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Jul 2013
Price :
$35
*
At a glance
- Drugs Alpha 1-antitrypsin (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 10 Jul 2013 Status changed from planning to recruiting, based on information in an Omni Bio Pharmaceutical media release.
- 10 Jul 2013 Financial support from the University of Michigan Cancer Center and the Leukemia and Lymphoma Society has been announced by Omni Bio Pharmaceutical. The University of Michigan Cancer Center is commencing the trial as reported in an Omni Bio media release.
- 17 Jan 2012 New trial record